A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy,
tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in
Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and
Part 2 (dose expansion).